ORGANOGENESIS APLIGRAF SKIN GRAFT PMA APPROVABLE FOR VENOUS ULCERS, PANEL SAYS; PRODUCT EFFECTIVE ONLY FOR WOUNDS MORE THAN ONE YEAR OLD
This article was originally published in The Gray Sheet
Executive Summary
Organogenesis's Apligraf (Graftskin) living skin graft is approvable for use in treating partial- and full-thickness skin loss from ulcers of venous etiology, FDA's General and Plastic Surgery Devices Panel concluded in a 5-4 vote at its Jan. 29 meeting in Gaithersburg, Maryland. In recommending approval for the premarket approval application, the advisory committee concurred with company labeling stating that Graftskin is "particularly beneficial" in treating venous ulcers of duration greater than one year.
You may also be interested in...
Apligraf Reduces Healing Time For Diabetic Foot Ulcers By 30%
Organogenesis' Apligraf living skin construct reduces the time it takes diabetic foot ulcers to heal by almost one-third, the company says.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.